Literature DB >> 507915

Use of growth hormone-gel.

B Lippe, S D Frasier, S A Kaplan.   

Abstract

We evaluated the efficacy of a depot preparation of growth hormone (GH) in a 15% gelatin solution (GH-gel) in the treatment of 15 growth hormone-deficient children. The studies were designed to see if prolonging absorption of GH to achieve lower more physiological concentrations of GH in plasma would decrease the frequency of injection, reduce the amount of GH needed for effective therapeutic response, and improve the response to long-term treatment. We found that after a single dose of GH-gel the plasma concentrations of GH were lower than those achieved after the standard aqueous preparation. The preparation was efficacious in promoting growth and our 1st study of 6 patients suggested that GH-gel given twice a week had a growth response equal to that of the three-times a week aqueous schedule. However both schedules resulted in the frequently observed decreased growth rate during the second treatment year. Our 2nd study, attempting to ameliorate this waning effect by using the GH-gel preparation twice a week in a weight-adjusted dose during the entire second year did not resolve the problem. Thus, GH in depot gel results in more physiological plasma concentrations of GH and may be beneficial in reducing the quantity of hormone needed and the injection frequency but it does not offer a solution to the waning response to the long-term administration of GH.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 507915      PMCID: PMC1545780          DOI: 10.1136/adc.54.8.609

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  16 in total

1.  Long-term effects of human growth hormone (Li) in a pituitary dwarf.

Authors:  R F ESCAMILLA; J J HUTCHINGS; W C DEAMER; C H LI; P H FORSHAM
Journal:  J Clin Endocrinol Metab       Date:  1961-06       Impact factor: 5.958

2.  Treatment of a pituitary dwarf with human growth hormone.

Authors:  M S RABEN
Journal:  J Clin Endocrinol Metab       Date:  1958-08       Impact factor: 5.958

3.  Reversible hypothyroidism in growth hormone-deficient children treated with human growth hormone.

Authors:  B M Lippe; A J Van Herle; S H LaFranchi; R P Uller; N Lavin; S A Kaplan
Journal:  J Clin Endocrinol Metab       Date:  1975-04       Impact factor: 5.958

4.  Simultaneous assessment of growth hormone and ACTH reserve in children pretreated with diethylstilbestrol.

Authors:  B Lippe; S L Wong; S A Kaplan
Journal:  J Clin Endocrinol Metab       Date:  1971-12       Impact factor: 5.958

5.  Results of intermittent human growth hormone (HGH) therapy in hypopituitary dwarfism.

Authors:  R T Kirkland; J L Kirkland; L Librik; G W Clayton
Journal:  J Clin Endocrinol Metab       Date:  1973-08       Impact factor: 5.958

6.  Growth hormone release during sleep in growth retarded children.

Authors:  C J Eastman; L Lazarus
Journal:  Arch Dis Child       Date:  1973-07       Impact factor: 3.791

7.  Collaborative study of the effects of human growth hormone in growth hormone deficiency. II. Development and significance of antibodies to human growth hormone during the first year of therapy.

Authors:  S D Frasier; T Aceto; A B Hayles; M L Parker; H F Meyer-Bahlburg
Journal:  J Clin Endocrinol Metab       Date:  1974-01       Impact factor: 5.958

8.  Sulphation factor activity and growth rate during long-term treatment of patients with pituitary dwarfism with human growth hormone.

Authors:  K Hall; P Olin
Journal:  Acta Endocrinol (Copenh)       Date:  1972-03

9.  Collaborative study of the effects of human growth hormone in growth hormone deficiency: IV. Treatment with low doses of human growth hormone based on body weight.

Authors:  S D Frasier; T Aceto; A B Hayles; V G Mikity
Journal:  J Clin Endocrinol Metab       Date:  1977-01       Impact factor: 5.958

10.  Effectiveness of long-term human growth hormone therapy for short stature in children with growth hormone deficiency.

Authors:  L F Soyka; H H Bode; J D Crawford; F J Flynn
Journal:  J Clin Endocrinol Metab       Date:  1970-01       Impact factor: 5.958

View more
  6 in total

Review 1.  Stunted growth with more or less normal appearance.

Authors:  J R Bierich; H Enders; U Heinrich; R Huenges; M B Ranke; D Schoenberg
Journal:  Eur J Pediatr       Date:  1982-12       Impact factor: 3.183

Review 2.  Spotlight on Lonapegsomatropin Once-Weekly Injection and Its Potential in the Treatment of Growth Hormone Deficiency in Pediatric Patients.

Authors:  Bradley S Miller; Kevin C J Yuen
Journal:  Drug Des Devel Ther       Date:  2022-06-29       Impact factor: 4.319

Review 3.  Long-Acting Growth Hormone Preparations - Current Status and Future Considerations.

Authors:  Bradley S Miller; Eric Velazquez; Kevin C J Yuen
Journal:  J Clin Endocrinol Metab       Date:  2020-06-01       Impact factor: 5.958

Review 4.  The rationale and design of TransCon Growth Hormone for the treatment of growth hormone deficiency.

Authors:  Kennett Sprogøe; Eva Mortensen; David B Karpf; Jonathan A Leff
Journal:  Endocr Connect       Date:  2017-09-25       Impact factor: 3.335

Review 5.  Usefulness and Potential Pitfalls of Long-Acting Growth Hormone Analogs.

Authors:  Kevin C J Yuen; Bradley S Miller; Cesar L Boguszewski; Andrew R Hoffman
Journal:  Front Endocrinol (Lausanne)       Date:  2021-02-24       Impact factor: 5.555

6.  A long-acting human growth hormone with delayed clearance (VRS-317): results of a double-blind, placebo-controlled, single ascending dose study in growth hormone-deficient adults.

Authors:  Kevin C J Yuen; Gerard S Conway; Vera Popovic; George R Merriam; Timothy Bailey; Amir H Hamrahian; Beverly M K Biller; Mark Kipnes; Jerome A Moore; Eric Humphriss; George M Bright; Jeffrey L Cleland
Journal:  J Clin Endocrinol Metab       Date:  2013-04-12       Impact factor: 5.958

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.